CohBar

CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. It focuses on treatments of diseases, which include diabetes, obesity, fatty liver disease and non-alcoholic steatohepatitis, cancer, Alzheimer's disease, and atherosclerosis. The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Menlo Park, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CohBar, Inc. is a clinical stage biotechnology company, which engages in the research and development of mitochondria-based therapeutics targeting chronic and age-related diseases. The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Menlo Park, CA.

Anti-tumor effects demonstrated in vivo in preclinical melanoma immuno-oncology model Anti-tumor effects demonstrated in vivo in preclinical melanoma immuno-oncology model

CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis

New results also confirm anti-inflammatory effect New results also confirm anti-inflammatory effect

CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis

CohBar's (CWBR) CEO Steve Engle on Q3 2019 Results - Earnings Call Transcript

CohBar - The Pioneer In Mitochondrial Drugs

MENLO PARK, Calif., Oct.  23, 2019  (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, today announced the appointment of Misha Petkevich to its Board of Directors. Mr. Petkevich brings to the company more than three decades of financial and investment experience with life sciences companies in leadership roles at V2M Capital, Robertson Stephens & Co. and Hambrecht & Quist.

CohBar Expands Board with Biotech Veteran Misha Petkevich

MENLO PARK, Calif., Oct.  15, 2019  (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present at the 2019 BIO Investor Forum, which is being held October 22-23 at the Westin St. Francis Hotel in San Francisco, CA. The BIO Investor Forum explores investment trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2020.

CohBar to Present at the 2019 BIO Investor Forum

MENLO PARK, Calif., Sept.  18, 2019  (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present at the 2019 Cantor Global Healthcare Conference, which is being held October 2-4 at the Intercontinental New York Barclay Hotel in New York City. The conference features more than 200 innovative public and private companies offering insights into developing trends shaping healthcare today.

CohBar to Present at the 2019 Cantor Global Healthcare Conference

CohBar, Inc. (CWBR) CEO Steven Engle on Q2 2019 - Earnings Call Transcript

CohBar Inc. (CWBR) Interim CEO Philippe Calais on Q1 2019 Results - Earnings Call Transcript

CohBar Inc. (CWBR) CEO Philippe Calais on Q4 2018 Results - Earnings Call Transcript

News for CohBar Stock (CWBR)